Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ODC1 | P11926 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5933173 | 1.00 | CYP3A4 (0.47) | CYP3A4DNM1TSHRMEN1KMT2A | |
| SCHEMBL238386 | 0.97 | — | — | |
| SCHEMBL5932166 | 0.94 | CYP3A4 (0.47) | CYP3A4DNM1TSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3993420 | 0.94 | — | — | |
| SCHEMBL5933092 | 0.94 | CYP3A4 (0.47) | CYP3A4DNM1TSHRMEN1KMT2A | |
| SCHEMBL11715376 | 0.93 | CYP3A4 (0.42) | CYP3A4DNM1TSHRMEN1KMT2A | |
| SCHEMBL11285048 | 0.92 | HTT (0.47) | CYP3A4DNM1TSHRMEN1KMT2A | |
| SCHEMBL5933618 | 0.92 | DNM1 (0.46) | CYP3A4DNM1TSHRMEN1KMT2A | |
| SCHEMBL16158120 | 0.90 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL14231347 | 0.90 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634474-B1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER INFECTIONS AND AUTOIMMUNE DISORDERS | AVENCELL EUROPE GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12173063-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders | AVENCELL EUROPE GMBH (DE) | 2024-12-24 | — | — | US | disclosed |
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230381113-A1 | POLYMERS AND NANOPARTICLE FORMULATIONS FOR SYSTEMIC NUCLEIC ACID DELIVERY | THE JOHNS HOPKINS UNIVERSTY | 2023-11-30 | — | — | US | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230272066-A1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS | AVENCELL THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-10 | — | — | US | disclosed |
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2023-04-25 | — | — | US | disclosed |
| US-11560426-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders | AVENCELL EUROPE GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4116298-A1 | PIPERIDINEDIONE DERIVATIVE | Innocure Therapeutics, Inc. (KR) | 2023-01-11 | — | — | EP | disclosed |
| US-8076288-B2 | Hybrid polypeptides having glucose lowering activity | AMYLIN PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | BRACCO INTERNATIONAL B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| CN-1961000-B | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS INC | 2011-05-04 | — | — | CN | disclosed |
| US-7884183-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2011-02-08 | — | — | US | disclosed |
| US-20100311903-A1 | Photonic Shell-Core Cross Linked and Functionalized Nanostructures for Biological Applications | MALLINCKRODT LLC | 2010-12-09 | — | — | US | disclosed |
| US-7820621-B2 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2010-10-26 | — | — | US | disclosed |
| CN-101432025-A | Peptide-peptidase inhibitor conjugates and methods of using same | AMYLIN PHARMACEUTICALS INC (US) | 2009-05-13 | — | — | CN | disclosed |
| CN-1961000-A | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS INC (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20060293232-A1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272066-A1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS | CD74, HAVCR2, CD4 | CYP3A4 4847/4885DNM1 3788/4885TSHR 746/4885 |
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, HBB, IGF1R | CYP3A4 4034/4885DNM1 866/4885TSHR 1343/4885 |
| US-20060293232-A1 | Hybrid polypeptides with selectable properties | IAPP, IGFBP1, PGF | CYP3A4 4838/4885DNM1 239/4885TSHR 808/4885 |
| US-20230381113-A1 | POLYMERS AND NANOPARTICLE FORMULATIONS FOR SYSTEMIC NUCLEIC ACID DELIVERY | SARNP, EEA1, PHAX | CYP3A4 4581/4885DNM1 1042/4885TSHR 3202/4885 |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, CUL1, PSMB10 | CYP3A4 4750/4885DNM1 2444/4885TSHR 3860/4885 |
| US-11560426-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders | CD74, HAVCR2, CD4 | CYP3A4 4862/4885DNM1 3649/4885TSHR 748/4885 |
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | PLAUR, CD47, CD14 | CYP3A4 4736/4885DNM1 2864/4885TSHR 1054/4885 |
| US-12173063-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders | CD74, HAVCR2, CD4 | CYP3A4 4847/4885DNM1 3788/4885TSHR 746/4885 |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | VCAM1, FLT1, EDNRA | CYP3A4 4836/4885DNM1 640/4885TSHR 1504/4885 |
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | RARG, RARA, RARB | CYP3A4 4109/4885DNM1 1743/4885TSHR 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.